Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology.
Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, Morosi C, Camerini T, Carrara M, Pellizzari S, Negri A, Aliberti G, Sposito C, Bhoori S, Facciorusso A, Civelli E, Lanocita R, Padovano B, Migliorisi M, De Nile MC, Seregni E, Marchianò A, Crippa F, Mazzaferro V. Chiesa C, et al. Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1718-1738. doi: 10.1007/s00259-015-3068-8. Epub 2015 Jun 27. Eur J Nucl Med Mol Imaging. 2015. PMID: 26112387
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan.
Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, Sposito C, Morosi C, Civelli E, Lanocita R, Camerini T, Bampo C, Bhoori S, Seregni E, Marchianò A, Mazzaferro V, Bombardieri E. Chiesa C, et al. Q J Nucl Med Mol Imaging. 2011 Apr;55(2):168-97. Q J Nucl Med Mol Imaging. 2011. PMID: 21386789 Review.
Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship.
Chiesa C, Mira M, Bhoori S, Bormolini G, Maccauro M, Spreafico C, Cascella T, Cavallo A, De Nile MC, Mazzaglia S, Capozza A, Tagliabue G, Brusa A, Marchianò A, Seregni E, Mazzaferro V. Chiesa C, et al. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3018-3032. doi: 10.1007/s00259-020-04845-4. Epub 2020 May 25. Eur J Nucl Med Mol Imaging. 2020. PMID: 32451604
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregni E, Gianni MA, Bombardieri E. Chiesa C, et al. Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1745-57. doi: 10.1007/s00259-009-1141-x. Epub 2009 May 20. Eur J Nucl Med Mol Imaging. 2009. PMID: 19455328 Clinical Trial.
273 results